{"id":61473,"date":"2025-06-23T22:04:02","date_gmt":"2025-06-23T20:04:02","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\/"},"modified":"2025-06-23T22:04:02","modified_gmt":"2025-06-23T20:04:02","slug":"seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\/","title":{"rendered":"Seek Labs Maps Measles Virus with BioSeeker\u2122, Opening the Door to First-Ever Programmable Antiviral Therapeutic Amid Global Outbreaks"},"content":{"rendered":"<div>\n<p>SALT LAKE CITY&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/ArtificialIntelligence?src=hash\" target=\"_blank\">#ArtificialIntelligence<\/a>&#8211;Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced the successful mapping of conserved therapeutic targets within the measles virus (MeV) genome using BioSeeker\u2122, the company\u2019s proprietary AI-powered discovery engine. Amid rising measles outbreaks worldwide, this breakthrough marks a foundational step toward developing the world\u2019s first programmable antiviral therapeutic for measles, leveraging Seek Labs\u2019 CRISPR-based Programmable Target Ablation Platform (PTAP\u2122).<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20250623150390\/en\/2504397\/5\/Seek_Labs_Logo_Lower_Color.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250623150390\/en\/2504397\/22\/Seek_Labs_Logo_Lower_Color.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20250623150390\/en\/2504397\/5\/Seek_Labs_Logo_Lower_Color.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250623150390\/en\/2504397\/21\/Seek_Labs_Logo_Lower_Color.jpg\"><\/a><\/p>\n<p>\nBioSeeker scanned thousands of publicly available measles virus isolates, identifying a multiplexed set of high-impact, PTAP-compatible genomic targets (stable, conserved regions most critical to viral replication). These sites form a blueprint for CRISPR-based \u201cseek-and-destroy\u201d therapeutics capable of irreversibly disabling the virus with speed, specificity, and resilience against resistance.<\/p>\n<p>\n\u201cThis is exactly why we built BioSeeker; to deliver smarter, faster weapons against viral diseases that still lack effective treatments,\u201d said Jared Bauer, CEO of Seek Labs. \u201cThere are no targeted therapeutics for measles once infection occurs. With BioSeeker, we can now design a precision treatment that shuts down the virus at its source, unlocking a powerful new paradigm for global health.\u201d<\/p>\n<p>\n<b>A Game-Changing Response to the Measles Crisis<\/b><\/p>\n<p>\nMeasles is one of the most contagious viruses in the world, spreading through airborne droplets and capable of causing severe complications, which include pneumonia, encephalitis, and death. Recent surges, such as the nearly 200,000 cases globally in early 2025, have placed renewed strain on public health systems and highlight the urgent need for scalable antiviral interventions.<\/p>\n<p>\nThe urgency of this breakthrough is underscored by Utah&#8217;s recent confirmation of its first measles case amid an ongoing national outbreak. As Seek Labs is headquartered in Salt Lake City, this development brings the crisis closer to home and emphasizes a critical need for accelerated antiviral solutions, especially in areas where vaccination rates remain low or immunity wanes.<\/p>\n<p>\nWhile Seek Labs is not advancing this candidate in-house, the company will make its complete BioSeeker-generated measles guide set available to qualified partners and is actively seeking collaborators to accelerate preclinical development.<\/p>\n<p>\n\u201cWe\u2019ve done the foundational work and now we\u2019re inviting bold partners to help turn it into a breakthrough,\u201d said Kim Wirthlin, Chief Strategy Officer. \u201cThis is a first-of-its-kind opportunity to co-develop a targeted antiviral for measles and reshape how the world responds to this disease.\u201d<\/p>\n<p>\n<b>Part of a Global Disease Atlas to Outpace Emerging Threats<\/b><\/p>\n<p>\nThis milestone is part of Seek Labs\u2019 broader initiative to build a <i>Global Disease Atlas, <\/i>a real-time, AI-powered genomic map of the world\u2019s most dangerous pathogens. The Atlas is on track to map over 95% of high-burden viral threats across both human and animal health, guiding the development of pan-pathogen, programmable therapeutics and diagnostics designed to adapt faster than viral evolution. Powered by BioSeeker, the Atlas enables faster decision-making, smarter intervention points, and scalable innovation across public health, biodefense, and pandemic preparedness.<\/p>\n<p>\nSeek Labs is actively partnering with biopharma, government, and global health organizations to move these discoveries into the clinic. Organizations interested in licensing, partnerships, or deploying these innovations for public health impact are encouraged to contact Seek Labs directly.<\/p>\n<p>\n<b>About Seek Labs<\/b><\/p>\n<p>\nAt Seek Labs, we don\u2019t wait for change\u2014we build it. We\u2019re seeking the breakthroughs the world can\u2019t wait for by developing programmable \u201cseek and destroy\u201d therapeutics and point-of-care molecular diagnostics that close the gap between outbreak and intervention. Powered by our AI discovery engine, BioSeeker\u2122, these platforms form a full-stack development engine\u2014from target discovery to real-world deployment\u2014designed to accelerate innovation and impact across global health.<\/p>\n<p>\nHeadquartered in Salt Lake City, Seek Labs is a proud member of BioHive, Utah\u2019s collaborative life sciences ecosystem. Together with our partners, we\u2019re building faster, smarter solutions for the world\u2019s most urgent health challenges.<\/p>\n<p>\n<b>Forward-Looking Statements and Regulatory Disclaimer<\/b><\/p>\n<p>\nThis press release includes forward-looking statements about Seek Labs\u2019 technologies, development plans, and partnership opportunities. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ. The technologies described are investigational and have not been reviewed or approved by the FDA or any other regulatory authority for clinical or commercial use.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nBridget Baldwin, Director of Communications, <a target=\"_blank\" href=\"&#109;&#x61;i&#108;&#x74;o&#58;&#x63;o&#109;&#x6d;u&#110;&#x69;&#99;&#x61;&#x74;&#105;&#x6f;&#x6e;&#115;&#x40;s&#101;&#x65;k&#108;&#x61;b&#115;&#x2e;c&#111;&#x6d;\" rel=\"nofollow\" shape=\"rect\">&#x63;&#111;&#x6d;&#x6d;&#117;&#x6e;&#x69;&#99;&#x61;&#x74;&#105;&#x6f;&#x6e;s&#x40;&#x73;e&#x65;&#107;l&#x61;&#98;s&#x2e;&#99;o&#x6d;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>SALT LAKE CITY&#8211;(BUSINESS WIRE)&#8211;#ArtificialIntelligence&#8211;Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced the successful mapping of conserved therapeutic targets within the measles virus (MeV) genome using BioSeeker\u2122, the company\u2019s proprietary AI-powered discovery engine. Amid rising measles outbreaks worldwide, this breakthrough marks a foundational step &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61473","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Seek Labs Maps Measles Virus with BioSeeker\u2122, Opening the Door to First-Ever Programmable Antiviral Therapeutic Amid Global Outbreaks - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Seek Labs Maps Measles Virus with BioSeeker\u2122, Opening the Door to First-Ever Programmable Antiviral Therapeutic Amid Global Outbreaks - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SALT LAKE CITY&#8211;(BUSINESS WIRE)&#8211;#ArtificialIntelligence&#8211;Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced the successful mapping of conserved therapeutic targets within the measles virus (MeV) genome using BioSeeker\u2122, the company\u2019s proprietary AI-powered discovery engine. Amid rising measles outbreaks worldwide, this breakthrough marks a foundational step ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-23T20:04:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250623150390\/en\/2504397\/22\/Seek_Labs_Logo_Lower_Color.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Seek Labs Maps Measles Virus with BioSeeker\u2122, Opening the Door to First-Ever Programmable Antiviral Therapeutic Amid Global Outbreaks\",\"datePublished\":\"2025-06-23T20:04:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\\\/\"},\"wordCount\":723,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250623150390\\\/en\\\/2504397\\\/22\\\/Seek_Labs_Logo_Lower_Color.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\\\/\",\"name\":\"Seek Labs Maps Measles Virus with BioSeeker\u2122, Opening the Door to First-Ever Programmable Antiviral Therapeutic Amid Global Outbreaks - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250623150390\\\/en\\\/2504397\\\/22\\\/Seek_Labs_Logo_Lower_Color.jpg\",\"datePublished\":\"2025-06-23T20:04:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250623150390\\\/en\\\/2504397\\\/22\\\/Seek_Labs_Logo_Lower_Color.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250623150390\\\/en\\\/2504397\\\/22\\\/Seek_Labs_Logo_Lower_Color.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Seek Labs Maps Measles Virus with BioSeeker\u2122, Opening the Door to First-Ever Programmable Antiviral Therapeutic Amid Global Outbreaks\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Seek Labs Maps Measles Virus with BioSeeker\u2122, Opening the Door to First-Ever Programmable Antiviral Therapeutic Amid Global Outbreaks - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\/","og_locale":"en_US","og_type":"article","og_title":"Seek Labs Maps Measles Virus with BioSeeker\u2122, Opening the Door to First-Ever Programmable Antiviral Therapeutic Amid Global Outbreaks - Pharma Trend","og_description":"SALT LAKE CITY&#8211;(BUSINESS WIRE)&#8211;#ArtificialIntelligence&#8211;Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced the successful mapping of conserved therapeutic targets within the measles virus (MeV) genome using BioSeeker\u2122, the company\u2019s proprietary AI-powered discovery engine. Amid rising measles outbreaks worldwide, this breakthrough marks a foundational step ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\/","og_site_name":"Pharma Trend","article_published_time":"2025-06-23T20:04:02+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250623150390\/en\/2504397\/22\/Seek_Labs_Logo_Lower_Color.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Seek Labs Maps Measles Virus with BioSeeker\u2122, Opening the Door to First-Ever Programmable Antiviral Therapeutic Amid Global Outbreaks","datePublished":"2025-06-23T20:04:02+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\/"},"wordCount":723,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250623150390\/en\/2504397\/22\/Seek_Labs_Logo_Lower_Color.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\/","url":"https:\/\/pharma-trend.com\/en\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\/","name":"Seek Labs Maps Measles Virus with BioSeeker\u2122, Opening the Door to First-Ever Programmable Antiviral Therapeutic Amid Global Outbreaks - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250623150390\/en\/2504397\/22\/Seek_Labs_Logo_Lower_Color.jpg","datePublished":"2025-06-23T20:04:02+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250623150390\/en\/2504397\/22\/Seek_Labs_Logo_Lower_Color.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250623150390\/en\/2504397\/22\/Seek_Labs_Logo_Lower_Color.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/seek-labs-maps-measles-virus-with-bioseeker-opening-the-door-to-first-ever-programmable-antiviral-therapeutic-amid-global-outbreaks\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Seek Labs Maps Measles Virus with BioSeeker\u2122, Opening the Door to First-Ever Programmable Antiviral Therapeutic Amid Global Outbreaks"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61473","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61473"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61473\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61473"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61473"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61473"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}